TY - JOUR
T1 - Everolimus in anaplastic thyroid cancer
T2 - A case series
AU - Harris, Ethan J.
AU - Hanna, Glenn J.
AU - Chau, Nicole
AU - Rabinowits, Guilherme
AU - Haddad, Robert
AU - Margalit, Danielle N.
AU - Schoenfeld, Jonathan
AU - Tishler, Roy B.
AU - Barletta, Justine A.
AU - Nehs, Matthew
AU - Janne, Pasi
AU - Huang, Julian
AU - Groden, Phillip
AU - Kacew, Alec
AU - Lorch, Jochen
N1 - Publisher Copyright:
Copyright © 2019 Harris, Hanna, Chau, Rabinowits, Haddad, Margalit, Schoenfeld, Tishler, Barletta, Nehs, Janne, Huang, Groden, Kacew and Lorch.
PY - 2019
Y1 - 2019
N2 - Background: Anaplastic thyroid cancer (ATC) is a very aggressive disease and accounts for over 50% of thyroid-cancer related deaths. mTOR inhibition has shown anti-tumor activity in ATC. We report our experience treating patients with ATC with everolimus off-protocol. Methods: Patients with confirmed ATC and treated with everolimus at DFCI were identified and reviewed retrospectively. NexGen sequencing was performed, and radiologic responses were correlated with mutational profile. Results: Five patients were treated from 2013 to 2016. Three patients had a response, which included one patient who achieved a partial response for 27.9 months, and two patients who had stable disease for 3.7 and 5.9 months, respectively. Genomic analysis was available in two patients and revealed that the partial responder had mutations involving the PI3K/mTOR pathway. Conclusion: Everolimus has anti-tumor activity in ATC, and responses may correlate with mutations involving the PI3K/mTOR pathway. Further studies are warranted.
AB - Background: Anaplastic thyroid cancer (ATC) is a very aggressive disease and accounts for over 50% of thyroid-cancer related deaths. mTOR inhibition has shown anti-tumor activity in ATC. We report our experience treating patients with ATC with everolimus off-protocol. Methods: Patients with confirmed ATC and treated with everolimus at DFCI were identified and reviewed retrospectively. NexGen sequencing was performed, and radiologic responses were correlated with mutational profile. Results: Five patients were treated from 2013 to 2016. Three patients had a response, which included one patient who achieved a partial response for 27.9 months, and two patients who had stable disease for 3.7 and 5.9 months, respectively. Genomic analysis was available in two patients and revealed that the partial responder had mutations involving the PI3K/mTOR pathway. Conclusion: Everolimus has anti-tumor activity in ATC, and responses may correlate with mutations involving the PI3K/mTOR pathway. Further studies are warranted.
KW - Anaplastic thyroid cancer (ATC)
KW - Exceptional responder
KW - MTOR inhibition in head and neck cancer
KW - PI3K mTOR
KW - Precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85063276608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063276608&partnerID=8YFLogxK
U2 - 10.3389/fonc.2019.00106
DO - 10.3389/fonc.2019.00106
M3 - Article
C2 - 30863722
AN - SCOPUS:85063276608
SN - 2234-943X
VL - 9
JO - Frontiers in Oncology
JF - Frontiers in Oncology
IS - FEB
M1 - 106
ER -
